Pure Global

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma - Trial NCT06226350

Access comprehensive clinical trial information for NCT06226350 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong New Time Pharmaceutical Co., LTD and is currently Completed. The study focuses on Cervical Cancer. Target enrollment is 29 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06226350
Phase 2
Completed
drug
Trial Details
ClinicalTrials.gov • NCT06226350
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer

Study Focus

Cervical Cancer

Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection

Interventional

drug

Sponsor & Location

Shandong New Time Pharmaceutical Co., LTD

Shandong, China

Timeline & Enrollment

Phase 2

Mar 04, 2021

Jan 03, 2024

29 participants

Primary Outcome

Objective tumor response rate (ORR) assessed by RECIST1.1

Summary

This study was an open, single-arm, enriched, multicenter Phase II study.

ICD-10 Classifications

Severe cervical dysplasia, not elsewhere classified
Mild cervical dysplasia
Moderate cervical dysplasia
Carcinoma in situ: Cervix, unspecified
Cervical root disorders, not elsewhere classified

Data Source

ClinicalTrials.gov

NCT06226350

Non-Device Trial